Laurent Morin has a total of 307 co-authors. Here are the top co-authors by number of shared publications:

  • Valérie Attali

    Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France; AP-HP, Groupe Hospitalier Universitaire APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, Service des Pathologies du Sommeil, Département R3S, Paris, France

    4 shared publications
  • Bernard Pigearias

    Laboratoire du sommeil, Nice, France

    3 shared publications
  • Christelle Monaca

    Hôpital Roger Salengro, Neurophysiologie Clinique, Lille, France

    3 shared publications
  • Damien Leger

    AP-HP, Hôpital Hôtel Dieu, Centre du Sommeil et de la Vigilance, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France

    3 shared publications
  • Eric Mullens

    Fondation Bon Sauveur, Laboratoire du Sommeil, Albi, France

    3 shared publications
  • Jean-Marc Collet

    AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Stomatologie et Chirurgie Maxillo-Faciale, Paris, France

    3 shared publications

Latest Publications

  • Open Access

    Exploring Relevance of Graded Sputum Production in Stable COPD in Clinical Practice

    by Laurent Morin, Jean-Christian Borel, Nathalie Arnol, Bernard Aguilaniu

    Sputum production, assessed by pulmonologists during routine clinical practice, can enhance the phenotypic characterization of COPD.

  • Open Access

    Feasibility of home initiation of an airway clearance device (SIMEOX) by telecare in people with non-cystic fibrosis bronchiectasis: a pilot study

    by Rebecca Hamidfar, Marlene Murris-Espin, Marie Mahot, Raphael Abouly, Hughes Gauchez, Sophie Jacques, Eloise Joffray, Nathalie Arnol, Laurent Morin, Sylvie Leroy, et al.

    Background Mucociliary clearance is a cornerstone of the management of people with non-cystic fibrosis bronchiectasis (NCFB). SIMEOX, an innovative device, could facilitate autonomous airway clearance, but its use requires specific training. We hypothesised that telecare would be an effective means to train people with NCFB in the handling of device and to monitor and promote device adherence. Objectives (1) To evaluate frequency of use of the SIMEOX for 10 weeks after telecare training. (2) To assess user satisfaction and clinical efficacy of the SIMEOX+telecare. Methods Multicentre, prospective, pilot study in adults with NCFB. A SIMEOX was provided to each participant at inclusion. Physiotherapists performed telecare sessions the first 2 weeks (3–5 sessions) for device training and every 10 days to reinforce motivation and provide technical support. Results 22 individuals were included, 21 analysed (38% male; mean±SD age 53±18 years; Bronchiectasis Severity Index 6.6±3.5). Fourteen participants (66.7%; 95% CI 43.1% to 84.5%) performed ≥3 SIMEOX sessions/week (self-reported adherence, primary outcome). Median (Q1; Q3) number of self-reported sessions/week for the whole group was 3.7 (1.8; 5.7). Adherence including web registration was 80.9%. At week 12, participant satisfaction rating was 9.0 (7.9; 10.0) on a 10-point visual analogue scale; respiratory function did not change but quality of life improved (COPD Assessment Test score −4.7, 95% CI −7.7 to −1.6, p=0.023; St Georges Respiratory Questionnaire −5.8, 95% CI −10.8 to −0.9, p=0.005). Conclusion Adherence to and satisfaction with the SIMEOX airway clearance device supported by telecare were high in people with NCFB. The clinical efficacy needs to be confirmed in a randomised controlled trial. Trial registration number NCT04742270.


  • Open Access

    Co-Design of a Voice-Based Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 (UpcomingVoice Study): Protocol for a Mixed Methods Study

    by Aurelie Fischer, Gloria A Aguayo, Pauline Oustric, Laurent Morin, Jerome Larche, Charles Benoy, Guy Fagherazzi

    Background: Between 10% and 20% of people with a COVID-19 infection will develop the so-called long COVID syndrome, which is characterized by fluctuating symptoms. Long COVID has a high impact on the quality of life of affected people, who often feel abandoned by the health care system and are demanding new tools to help them manage their symptoms. New digital monitoring solutions could allow them to visualize the evolution of their symptoms and could be tools to communicate with health care professionals (HCPs). The use of voice and vocal biomarkers could facilitate the accurate and objective monitoring of persisting and fluctuating symptoms. However, to assess the needs and ensure acceptance of this innovative approach by its potential users—people with persisting COVID-19–related symptoms, with or without a long COVID diagnosis, and HCPs involved in long COVID care—it is crucial to include them in the entire development process. Objective: In the UpcomingVoice study, we aimed to define the most relevant aspects of daily life that people with long COVID would like to be improved, assess how the use of voice and vocal biomarkers could be a potential solution to help them, and determine the general specifications and specific items of a digital health solution to monitor long COVID symptoms using vocal biomarkers with its end users. Methods: UpcomingVoice is a cross-sectional mixed methods study and consists of a quantitative web-based survey followed by a qualitative phase based on semistructured individual interviews and focus groups. People with long COVID and HCPs in charge of patients with long COVID will be invited to participate in this fully web-based study. The quantitative data collected from the survey will be analyzed using descriptive statistics. Qualitative data from the individual interviews and the focus groups will be transcribed and analyzed using a thematic analysis approach. Results: The study was approved by the National Research Ethics Committee of Luxembourg (number 202208/04) in August 2022 and started in October 2022 with the launch of the web-based survey. Data collection will be completed in September 2023, and the results will be published in 2024. Conclusions: This mixed methods study will identify the needs of people affected by long COVID in their daily lives and describe the main symptoms or problems that would need to be monitored and improved. We will determine how using voice and vocal biomarkers could meet these needs and codevelop a tailored voice-based digital health solution with its future end users. This project will contribute to improving the quality of life and care of people with long COVID. The potential transferability to other diseases will be explored, which will contribute to the deployment of vocal biomarkers in general. Trial Registration: ClinicalTrials.gov NCT05546918; https://clinicaltrials.gov/ct2/show/NCT05546918 International Registered Report Identifier (IRRID): DERR1-10.2196/46103


  • Open Access

    Co-Design of a Voice-Based Digital Health Solution to Monitor Persisting Symptoms Related to COVID-19 (UpcomingVoice Study): Protocol for a Mixed Methods Study (Preprint)

    by Aurelie Fischer, Gloria A Aguayo, Pauline Oustric, Laurent Morin, Jerome Larche, Charles Benoy, Guy Fagherazzi

    BACKGROUND Between 10% and 20% of people with a COVID-19 infection will develop the so-called long COVID syndrome, which is characterized by fluctuating symptoms. Long COVID has a high impact on the quality of life of affected people, who often feel abandoned by the health care system and are demanding new tools to help them manage their symptoms. New digital monitoring solutions could allow them to visualize the evolution of their symptoms and could be tools to communicate with health care professionals (HCPs). The use of voice and vocal biomarkers could facilitate the accurate and objective monitoring of persisting and fluctuating symptoms. However, to assess the needs and ensure acceptance of this innovative approach by its potential users—people with persisting COVID-19–related symptoms, with or without a long COVID diagnosis, and HCPs involved in long COVID care—it is crucial to include them in the entire development process. OBJECTIVE In the UpcomingVoice study, we aimed to define the most relevant aspects of daily life that people with long COVID would like to be improved, assess how the use of voice and vocal biomarkers could be a potential solution to help them, and determine the general specifications and specific items of a digital health solution to monitor long COVID symptoms using vocal biomarkers with its end users. METHODS UpcomingVoice is a cross-sectional mixed methods study and consists of a quantitative web-based survey followed by a qualitative phase based on semistructured individual interviews and focus groups. People with long COVID and HCPs in charge of patients with long COVID will be invited to participate in this fully web-based study. The quantitative data collected from the survey will be analyzed using descriptive statistics. Qualitative data from the individual interviews and the focus groups will be transcribed and analyzed using a thematic analysis approach. RESULTS The study was approved by the National Research Ethics Committee of Luxembourg (number 202208/04) in August 2022 and started in October 2022 with the launch of the web-based survey. Data collection will be completed in September 2023, and the results will be published in 2024. CONCLUSIONS This mixed methods study will identify the needs of people affected by long COVID in their daily lives and describe the main symptoms or problems that would need to be monitored and improved. We will determine how using voice and vocal biomarkers could meet these needs and codevelop a tailored voice-based digital health solution with its future end users. This project will contribute to improving the quality of life and care of people with long COVID. The potential transferability to other diseases will be explored, which will contribute to the deployment of vocal biomarkers in general. CLINICALTRIAL ClinicalTrials.gov NCT05546918; https://clinicaltrials.gov/ct2/show/NCT05546918 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/46103

  • Open Access

    Efficacy of the Simeox® Airway Clearance Technology in the Homecare Treatment of Children with Clinically Stable Cystic Fibrosis: A Randomized Controlled Trial

    by Dorota Sands, Katarzyna Walicka-Serzysko, Justyna Milczewska, Magdalena Postek, Natalia Jeneralska, Aleksandra Cichocka, Ewa Siedlecka, Urszula Borawska-Kowalczyk, Laurent Morin

    Background: Cystic fibrosis (CF) patients require regular airway clearance therapy (ACT). The aim of this study was to evaluate homecare therapeutic effects of a new ACT (Simeox®) added to the optimal standard of care, including home chest physiotherapy, in the treatment of clinically stable children. Methods: Forty pediatric CF patients (8–17 years old) with stable disease were randomized 1:1 in a single-center, prospective, open-label, cross-over trial into two groups: with or without Simeox®. Lung function (impulse oscillometry, spirometry, body plethysmography, multi-breath nitrogen washout) results, health-related quality of life, and safety were assessed during the study after 1 month of therapy at home. Results: A significant decrease in proximal airway obstruction (as supported by improvement in airway resistance at 20 Hz (R20Hz) and maximum expiratory flow at 75% of FVC (MEF75)) compared to the control group was observed after 1 month of therapy with the device. Lung-clearance index was stable in the study group, while it worsened in the control group. In addition, the device group demonstrated a significant increase in the Cystic Fibrosis Questionnaire—Revised (CFQ-R) physical score. No side effects were identified during the study. Conclusions: Simeox® may improve drainage of the airways in children with clinically stable CF and could be an option in chronic treatment of the disease.


  • Pulsated Herschel-Bulkley flows in two-dimensional channels: A model for mucus clearance devices

    by Antoine Galko, Simon Gsell, Umberto D'ORtona, Laurent Morin, Julien Favier

    Pressure oscillations applied to human airways can help patients to evacuate bronchial mucus, a highly non-Newtonian gel. To explore the fluid mechanics aspects of these therapies, we perform numerical simulations of pulsated non-Newtonian fluids in two-dimensional channels. The fluid rheology is modeled with the Herschel-Bulkley law, reproducing two essential nonlinear mechanical properties of the mucus, namely, the yield-stress and shear-thinning/thickening properties. The flow dynamics is simulated using the lattice-Boltzmann method over large ranges of the three main nondimensional parameters, i.e., the pulsation rate or Womersley number α, the flow index n quantifying the shear-thinning/thickening effect, and the Bingham number controlling the yield stress. The ratio between the fluctuating and average parts of the oscillatory forcing is examined through three typical cases: a purely oscillating flow, a weakly oscillating flow, and a strongly oscillating flow. For each configuration, specific sets of parameters are found to have a drastic effect on the dynamics of mucus plugs, which suggests new therapeutic strategies for patients suffering from bronchial obstructions.


  • Physiological effects of Simeox Airway Clearance Device in healthy adults

    by Laurent Morin, Damien Marino, Adrien Mithalal

    Introduction: Airway clearance devices (ACDs) assist in mobilizing retained secretions in lung diseases by increasing the velocity of expiratory flow. Aim: Aim of this study was to characterize oscillatory flow and negative expiratory pressure pulses generated by a new ACD in healthy subjects. Methods: 10 healthy adults activated a device (Simeox, PhysioAssist) generating intermittent pulses of intrapulmonary negative air pressure during relaxed exhalations. The procedure was repeated twice with 4 settings (25% or 100% power at 6 or 12 Hz frequency). Oscillatory flow and pressure pulses were measured at the mouth with a flow sensor (TSI, Certifier FA plus) to assess Maximal expiratory flow (MEF), maximal mid-expiratory flow (MMEF), Mean expiratory flow (EFmean), maximal expiratory flow amplitude (MEFamp), peak of negative expiratory pressure (NEPpeak) and maximal expiratory pressure amplitude (MEPamp). Results: 60% male, 34±12y, FEV1/FVC 90±14%. Data are presented in table 1. MEF (60 to 120 l/min) and MEFamp (70 to140 l/min) rates supported generation of high airflow velocity during exhalation over power range. Oscillatory flow was maintained at mid-exhalation. Low variability of data showed high reproducibility of flow and negative pressure pulses generated with Simeox during procedure. Range of pressure was safe (-10 to -60 mbar). Conclusions: These data suggest that Simeox may be an efficient and secure technology for airway clearance therapy.

  • Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of obstructive sleep apnea: ORCADES study 2-year follow-up data

    by Valérie Attali, Marie-Françoise Vecchierini, Jean-Marc Collet, Marie-Pia D'ORtho, Jean-Baptiste Kerbrat, Damien Leger, Florent Lavergne, Christelle Monaca, Pierre-Jean Monteyrol, Laurent Morin, et al.


  • Open Access

    Réduire les impacts environnementaux des aliments pour les animaux d'élevage

    by Aurélie Wilfart, Léonie Dusart, Bertrand Méda, Armelle Gac, Sandrine Espagnol, Laurent Morin, Yves Dronne, Florence Garcia-Launay

    L'alimentation animale peut représenter de 30 à 95 % des impacts environnementaux des produits animaux en sortie de ferme. Des données d’impacts environnementaux des matières premières ont été publiées mais il n’existait pas de données adaptées aux productions françaises. Le projet ECOALIM propose une base de données d’impacts environnementaux des matières premières utilisées en alimentation animale en France (154 matières premières disponibles). Dans le projet, une méthodologie de formulation multiobjectif a été développée pour produire des éco-aliments à impacts réduits et à prix maitrisé. Les impacts des aliments calculés à la tonne d'aliment sont ainsi modifiés de - 6 à - 14 % en production de porcs charcutiers et de + 4 à - 18 % en poulet de chair selon l'impact considéré, par rapport à une formulation à moindre coût classique et en considérant la disponibilité actuelle des MP. Dans le même temps, le prix de l'aliment est augmenté en moyenne d'1% en porc charcutier et de 3 % en poulet de chair. En biphase, avec restriction en porc charcutier, les impacts du kg de poids vif en sortie de ferme sont alors réduits de - 2 % à - 10 %. En poulet de chair, avec une alimentation classique en 3 phases, les impacts du kg de poids vif en sortie de ferme sont quant à eux réduits de - 2 à – 14 % (sauf pour l’occupation des terres qui augmente de 3%). A l’échelle territoriale, la réduction des impacts des aliments n’excède pas - 10 % en raison des compétitions entre filières pour les matières premières à faibles impacts.